News | June 24, 2022
Merck KGaA doubles HPAPI production capacity in Wisconsin
This new €59 million, 70,000 square foot facility, officially opened today, brings 50 new jobs to the area
This new €59 million, 70,000 square foot facility, officially opened today, brings 50 new jobs to the area
Redbiotec has a right to royalties on Eurocine Vaccines´ net sales of an approved HSV-2 vaccine, should such sales arise.
Next-generation booster vaccine candidate demonstrates potential to protect against COVID-19 variants of concern, including Omicron BA.1 and BA.2, with a favorable safety and tolerability profile
Companies concluded memorandum of understanding that Takeda will continue to provide distribution support for the Moderna COVID-19 vaccines for a transitional period
This agreement is in addition to the $92 million filling line expansion announced in November 2021
Trial will assess safety and antibody responses of NVX-CoV2515 to the Omicron variant of COVID-19
The study was conducted in equal laboratory conditions in the Spallanzani Institute in Italy on comparable sera samples from individuals vaccinated with Sputnik V and Pfizer with a similar level of IgG antibodies and virus-neutralizing activity (VNA) against Wuhan variant.
Approval follows CHMP recommendation for use in patients previously vaccinated with Vaxzevria or an EU-approved mRNA Covid-19 vaccine
Children 5 through 11 years of age are now authorized to receive a booster dose at least five months after the second dose of the two-dose primary series
At an affordable price, a researcher can process fresh samples of 10,000 cells immediately with a stable stopping point within two hours, simplifying sample management at the laboratory and limiting transcriptional changes
Subscribe To Our Newsletter & Stay Updated
